CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS

V. Limmroth, F. Barkhof, N. Desem, M.P. Diamond, G. Tachas

Research output: Contribution to journal › Article › Academic › peer-review

Cite this

@article{54c7edb39017408d86d6716e2dc84aab,

title = "CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS",

author = "V. Limmroth and F. Barkhof and N. Desem and M.P. Diamond and G. Tachas",

year = "2014",

doi = "10.1212/WNL.0000000000000926",

language = "Undefined/Unknown",

volume = "83",

pages = "1780--1788",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "20",

}

TY - JOUR

T1 - CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS

AU - Limmroth, V.

AU - Barkhof, F.

AU - Desem, N.

AU - Diamond, M.P.

AU - Tachas, G.

PY - 2014

Y1 - 2014

U2 - 10.1212/WNL.0000000000000926

DO - 10.1212/WNL.0000000000000926

M3 - Article

C2 - 25239835

VL - 83

SP - 1780

EP - 1788

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 20

ER -